L Guglielmetti1, J Jaffré1, C Bernard2, F Brossier1, N El Helali3, K Chadelat4, G Thouvenin4, B Dautzenberg5, B Henry6, M Jaspard6, H Guillot6, V Pourcher6, D Le Dû7, D Marigot-Outtandy8, F Mougari9, L Raskine9, B Rivoire10, C Andrejak11, V Jarlier1, A Aubry1, J Robert1, M Frechet-Jachym7, N Veziris12. 1. Sorbonne Université, Centre d'immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Laboratoire de Bactériologie-Hygiène, Assistance Publique-Hôpitaux de Paris (APHP), Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Paris. 2. Service de Biologie, Grand Hôpital de l'Est Francilien, Jossigny. 3. Plateforme de dosages des anti-infectieux, Groupe Hospitalier Paris Saint-Joseph, Paris. 4. APHP, Hôpital d'enfants Armand-Trousseau, Paris. 5. APHP, Pneumologie, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Paris. 6. Sorbonne Université, CIMI-Paris, APHP, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Paris. 7. Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges. 8. Sanatorium, Centre Hospitalier de Bligny, Briis-sous-Forges, APHP, Service de Médecine Aigue Spécialisée, Hôpital Raymond Poincaré, Garches. 9. APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Bactériologie-Virologie, Hôpitaux Universitaires Lariboisière-St Louis-Widal, Paris. 10. Service d'Aide Médicale Urgente Social, Paris. 11. Pneumologie, Centre Hospitalière Universitaire d'Amiens, Amiens. 12. Sorbonne Université, CIMI-Paris, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Département de Bactériologie, APHP, Hôpitaux Universitaires de l'Est Parisien, F-75012 Paris, France.
Abstract
SETTING: The World Health Organization (WHO) recommends that multidrug-resistant tuberculosis (MDR-TB) treatment should be managed in collaboration with multidisciplinary advisory committees (consilia). A formal national Consilium has been established in France since 2005 to provide a centralised advisory service for clinicians managing MDR-TB and extensively drug-resistant (XDR-TB) cases. OBJECTIVE: Review the activity of the French TB Consilium since its establishment. DESIGN: Retrospective description and analysis of the activity of the French TB Consilium. RESULTS: Between 2005 and 2016, 786 TB cases or contacts of TB cases were presented at the French TB Consilium, including respectively 42% and 79% of all the MDR-TB and XDR-TB cases notified in France during this period. Treatment regimens including bedaquiline and/or delamanid were recommended for 42% of the cases presented at the French TB Consilium since 2009. Patients were more likely to be presented at the French TB Consilium if they were born in the WHO Europe Region, had XDR-TB, were diagnosed in the Paris region, or had resistance to additional drugs than those defining XDR-TB. CONCLUSION: The French TB Consilium helped supervise appropriate management of MDR/XDR-TB cases and facilitated implementation of new drugs for MDR/XDR-TB treatment.
SETTING: The World Health Organization (WHO) recommends that multidrug-resistant tuberculosis (MDR-TB) treatment should be managed in collaboration with multidisciplinary advisory committees (consilia). A formal national Consilium has been established in France since 2005 to provide a centralised advisory service for clinicians managing MDR-TB and extensively drug-resistant (XDR-TB) cases. OBJECTIVE: Review the activity of the French TB Consilium since its establishment. DESIGN: Retrospective description and analysis of the activity of the French TB Consilium. RESULTS: Between 2005 and 2016, 786 TB cases or contacts of TB cases were presented at the French TB Consilium, including respectively 42% and 79% of all the MDR-TB and XDR-TB cases notified in France during this period. Treatment regimens including bedaquiline and/or delamanid were recommended for 42% of the cases presented at the French TB Consilium since 2009. Patients were more likely to be presented at the French TB Consilium if they were born in the WHO Europe Region, had XDR-TB, were diagnosed in the Paris region, or had resistance to additional drugs than those defining XDR-TB. CONCLUSION: The French TB Consilium helped supervise appropriate management of MDR/XDR-TB cases and facilitated implementation of new drugs for MDR/XDR-TB treatment.
Authors: O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-07-01 Impact factor: 3.427
Authors: Joseph Baruch Baluku; Richard Katuramu; Joshua Naloka; Enock Kizito; Martin Nabwana; Felix Bongomin Journal: BMC Pulm Med Date: 2021-07-10 Impact factor: 3.317